{"nctId":"NCT00142584","briefTitle":"Evaluation of the Long-term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With Hypertension","startDateStruct":{"date":"2005-08"},"conditions":["Hypertension"],"count":336,"armGroups":[{"label":"1-NEB","type":"EXPERIMENTAL","interventionNames":["Drug: Nebivolol (NEB)"]},{"label":"2-MET","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Metoprolol (MET)"]}],"interventions":[{"name":"Nebivolol (NEB)","otherNames":[]},{"name":"Metoprolol (MET)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Completion of previous nebivolol study\n* Stage 1-2 Hypertension (HTN) at baseline of first study\n\nExclusion Criteria:\n\n* Recent myocardial infarction or stroke\n* Contraindications to beta blocker therapy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Average Sitting Diastolic Blood Pressure (DBP) Taken at Trough at the End of Treatment Compared to Baseline","description":"The primary efficacy parameter was the change in the average trough sitting DBP at the end of treatment (Visit 10 or Early Termination) compared with baseline (baseline was defined as the baseline visit in Study NEB 310 \\[NCT00145210\\]).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.0","spread":"9.80"},{"groupId":"OG001","value":"-10.9","spread":"8.73"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Trough Sitting Diastolic Blood Pressure (DBP) at Each Study Visit (Visits 1 Through 9) Compared to Baseline","description":"Data for the analysis of the change from baseline in mean trough sitting DBP at each study visit (Visits 1 through 9) compared with baseline (baseline was defined as the baseline visit in Study NEB 310 \\[NCT00145210\\]) by treatment group are provided below.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.3","spread":"8.24"},{"groupId":"OG001","value":"-8.4","spread":"9.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.4","spread":"8.39"},{"groupId":"OG001","value":"-8.4","spread":"7.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.6","spread":"8.51"},{"groupId":"OG001","value":"-9.8","spread":"8.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.1","spread":"8.55"},{"groupId":"OG001","value":"-10.7","spread":"8.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.0","spread":"8.03"},{"groupId":"OG001","value":"-12.4","spread":"7.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.5","spread":"8.49"},{"groupId":"OG001","value":"-12.1","spread":"7.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.5","spread":"8.55"},{"groupId":"OG001","value":"-13.1","spread":"8.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.3","spread":"8.59"},{"groupId":"OG001","value":"-12.4","spread":"6.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.7","spread":"7.91"},{"groupId":"OG001","value":"-13.7","spread":"7.05"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Emergent Adverse Events (TEAEs)","description":"Summary of Participants that experienced one or more TEAEs by Treatment Group-Safety Population","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"150","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":252},"commonTop":["HEADACHE","Arthralgia","Back pain","Nasopharyngitis","Upper respiratory tract infection"]}}}